Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03079167
Other study ID # CTC0119
Secondary ID 12614000669695
Status Completed
Phase Phase 3
First received
Last updated
Start date May 14, 2016
Est. completion date April 30, 2024

Study information

Verified date June 2024
Source University of Sydney
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.


Description:

A lack of oxygen (hypoxia) or low blood supply (ischaemia) before or during birth can destroy cells in a newborn baby's brain. The damage caused by the lack of oxygen continues for some time afterwards. One way to try to reduce this damage is to induce hypothermia cooling the baby or just the baby's head for hours to days. Erythropoietin (Epo) given in the first week after birth shows promise as a treatment that may also help. This study is to find out whether Epo plus induced hypothermia (cooling) of near-term newborn babies who have suffered from low blood or oxygen supply to the brain at birth reduces death and disability in survivors at two years of age. The target population is 300 newborn term or near term infants (greater than or equal to 35+0 weeks gestation) with hypoxic ischaemic encephalopathy who are receiving, or planned to receive hypothermia and who are able to be recruited in time to allow study treatment to commence before 24 hours of age. This is a double blind, placebo controlled, parallel, 2 arm randomised, phase III multicentre trial, stratified by study site and by severity of encephalopathy at study entry. The treatment group of 150 infants will receive human recombinant Epo, 1000 IU/kg IV on days 1, 2, 3, 5 & 7 of life. The control group will receive 0.9% sodium chloride as a placebo on days 1, 2, 3, 5 & 7 of life. Families will be followed up every 6 months until the primary assessment of death and disability at 2 years of age.


Recruitment information / eligibility

Status Completed
Enrollment 313
Est. completion date April 30, 2024
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 23 Hours
Eligibility Inclusion Criteria: - Male or female infants born greater than or equal to 35+0 weeks gestation and able to be randomised less than 23 hours after birth - One or more of the following indicators of perinatal depression: 1. Apgar less than or equal to 5 at 10 minutes after birth, OR 2. Receiving ongoing resuscitation e.g. assisted ventilation (positive pressure ventilation or CPAP) or chest compressions at 10 minutes after birth, OR 3. on cord blood or arterial or venous blood obtained at less than 60 minutes after birth, either pH less than 7.00 OR base deficit greater than or equal to 12.0 mmol/L - Moderate to severe encephalopathy, defined between one and six hours after birth by one or both of the following: 1. 3 out of 6 modified Sarnat criteria indicating moderate/severe encephalopathy, OR 2. 2 out of 6 modified Sarnat criteria plus seizure(s) requiring anticonvulsant treatment (diagnosed either clinically or using EEG monitoring) at any time prior to randomisation - Hypothermia treatment initiated by 6 hours ofa ge; i.e. controlled whole-body cooling planned to continue for 72 hours to a target temperature (adjusted manually or with a device) and subsequent controlled re-warming - Study treatment planned to start within 24 hours after birth (as soon as feasible after randomisation) - At least one parent greater than or equal to 18 years of age - Anticipated ability to collect primary endpoint at 2 years of age - Signed, written informed parental consent Exclusion Criteria: - Contraindications to investigational product - Indication prior to randomisation for erythropoietin or any other erythropoietic stimulating agent to be given during the first two weeks of life - Severe intrauterine growth restriction (birth weight less than 1800g) - Suspected major chromosomal or congenital anomalies - Head circumference less than 3rd centile below the mean for gestation and gender - Infant for whom imminent withdrawal of care is being planned

Study Design


Intervention

Drug:
Epoetin Alfa

Normal saline


Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park South Australia
Australia Royal Prince Alfred Hospital Camperdown New South Wales
Australia Monash Medical Centre Clayton Victoria
Australia Canberra Hospital Garran Australian Capital Territory
Australia Mercy Hospital for Women Heidelberg Victoria
Australia Royal Women's & Brisbane Hospital Herston Queensland
Australia Royal Hobart Hospital Hobart Tasmania
Australia Nepean Hospital Kingswood New South Wales
Australia John Hunter Hospital New Lambton New South Wales
Australia Women's and Children's Hospital North Adelaide South Australia
Australia The Royal Children's Hospital Parkville Victoria
Australia The Royal Women's Hospital Parkville Victoria
Australia Royal Hospital for Women Randwick New South Wales
Australia Mater Mothers' Hospital South Brisbane Queensland
Australia Royal North Shore Hospital St Leonards New South Wales
Australia King Edward Memorial Hospital Subiaco Western Australia
Australia Princess Margaret Hospital Subiaco Western Australia
Australia Westmead Hospital Westmead New South Wales
New Zealand Auckland City Hospital Auckland
New Zealand Middlemore Hospital Auckland
New Zealand Christchurch Hospital Christchurch
New Zealand Waikato Hospital Hamilton
New Zealand Wellington Hospital Wellington
Singapore KK Women's and Children's Hospital Singapore

Sponsors (2)

Lead Sponsor Collaborator
University of Sydney National Health and Medical Research Council, Australia

Countries where clinical trial is conducted

Australia,  New Zealand,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other Distribution of overall disability Distribution of overall severity across 4 domains: 1) normal, 2) mild motor or cognitive deficit, 3) moderate/severe motor or cognitive deficit, and 4) death 2 years of age
Primary Composite measure of death or moderate/severe disability Moderate/severe disability is defined as any cerebral palsy and a Gross Motor Function Classification Scale (GMFCS) score greater than or equal to 1), or Bayley Scale of Infant Development III (BSDIII) less than or equal to 80 2 years of age
Secondary Death Death from any cause Any time from Day 1 of treatment to 2 years of age
Secondary Cerebral palsy (CP), assessed by paediatric assessment Any incidence of CP (any of quadriplegia, triplegia, hemiplegia, diplegia or monoplegia) 2 years of age
Secondary Moderate/severe motor deficit Composite of any incidence of CP (any of quadriparesis, CP, hemiparesis or diparesis) AND any level of functional impairment using the GMFCS greater than or equal to 1.0 2 years of age
Secondary Moderate/severe cognitive deficit Defined as a BSDIII cognitive score less than or equal to 80 2 years of age
Secondary Need for supplemental respiratory support (includes tracheostomy, ventilator, high flow nasal cannula, CPAP or oxygen dependency) Supplemental respiratory support includes tracheostomy, ventilator, high flow nasal cannula, CPAP or oxygen dependency 2 years of age
Secondary Need for nutritional support (includes gastrostomy or nasogastric feeds) Nutritional support includes gastrostomy or nasogastric feeds 2 years of age
Secondary Major cortical visual impairment by paediatric examination Impairment as assessed by paediatric assessment 2 years of age
Secondary Hearing impairment status by paediatric examination - requirement for hearing aids Defined as the requirement for hearing aids (either diagnosis of: Hears well or with only a little difficulty WITH a hearing aid OR Has severe hearing difficulty even with a hearing aid or hearing is not helped with an aid) 2 years of age
Secondary Epilepsy (history of 2 or more afebrile unprovoked seizures since discharge from neonatal unit where PAEAN study treatment was provided, or use of anticonvulsants at 2 years of age). Defined by history of 2 or more afebrile unprovoked seizures since discharge from neonatal unit where PAEAN study treatment was provided, or use of anticonvulsants at 2 years of age 2 years of age
Secondary Cost of healthcare and service utilisation Defined as a composite of parent completed questionnaire data and Medicare service use 2 years of age
Secondary Frequency of selected adverse events (AEs) of interest, including deaths Frequency of selected adverse events (AEs) of interest up to 30 days after the last study dose Up to 30 days post study treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05048550 - Babies in Glasses; a Feasibility Study. N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT05836610 - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates Phase 4
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Enrolling by invitation NCT02260271 - Florida Neonatal Neurologic Network
Terminated NCT01192776 - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) N/A
Completed NCT06344286 - The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE N/A
Recruiting NCT05901688 - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting NCT02894866 - Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy N/A
Recruiting NCT03682042 - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up N/A
Recruiting NCT03657394 - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries N/A
Withdrawn NCT03681314 - Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU) N/A
Completed NCT03485781 - Propofol-induced EEG Changes in Hypoxic Brain Injury
Not yet recruiting NCT06429007 - A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury Phase 2
Recruiting NCT05568264 - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit N/A
Not yet recruiting NCT06448780 - Dose Optimization of Caffeine for HIE Phase 1
Completed NCT02264808 - Developmental Outcomes
Completed NCT05687708 - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia N/A
Recruiting NCT06195345 - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)